ArticleAmerican journal of translational research2026
Clinical efficacy of percutaneous transhepatic biliary drainage for obstructive jaundice in pancreatic cancer and risk factors for postoperative pancreatitis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical efficacy of percutaneous transhepatic biliary drainage (PTBD) for obstructive jaundice in pancreatic cancer and identify the independent risk factors for postoperative pancreatitis after PTBD.
methodsA retrospective cohort study included 145 consecutive patients with pancreatic cancer admitted to Shanghai Seventh People's Hospital from June 2022 to June 2024, assigned to either the endoscopic retrograde biliary drainage (ERBD, n=72) group or the PTBD (n=73) group. The PTBD group was further subdivided into pancreatitis (n=11) and non-pancreatitis (n=62) subgroups. Clinical data were compared between groups. Univariate and Firth multivariate logistic regression analyses identified independent factors, with ROC curves evaluating predictive value.
resultsBaseline data were balanced between groups (all P>0.05). PTBD yielded more significant improvements in liver function and a shorter jaundice resolution time (all P<0.05), yet was associated with a significantly higher incidence of postoperative pancreatitis (P<0.05). High body mass index (BMI), Oddi sphincter dysfunction, and difficult intubation were independent risk factors (P<0.05), while external drainage was a protective factor (OR=0.064, P=0.023). A multivariate combined predictive model constructed from these factors exhibited excellent predictive efficacy (area under the curve (AUC) =0.960, 95% CI: 0.918-1.000).
conclusionPTBD effectively relieves obstructive jaundice and improves liver function. High-risk patients (elevated BMI, Oddi sphincter dysfunction, difficult intubation) require close monitoring, and prioritizing external drainage may reduce postoperative pancreatitis risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.